---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-056020"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2026-02-18T23:59:59+00:00"
generated_at: "2026-05-16T02:10:21.654852+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma reports $728.9M cash, obicetrapib regulatory decisions expected 2H26

## Summary
- Regulatory decisions from EMA, UK, Switzerland for obicetrapib monotherapy & FDC expected in 2H26.
- Cash position $728.9M at Dec 31, 2025; net loss $203.8M for FY2025.
- Topline data from RUBENS Phase 3 trial (type 2 diabetes/metabolic syndrome) expected by year-end 2026.
- PREVAIL CVOT blinded event rate through initial 12 months tracking in line with BROADWAY.
- Plan to initiate Alzheimer's disease trial in 2026 based on positive biomarker data from BROADWAY.

## SEC filing metadata
- accession: 0001193125-26-056020
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2026-02-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312526056020/0001193125-26-056020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312526056020/nams-20260218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-056020
- JSON: https://secwatch.observer/filing/0001193125-26-056020.json
- Plain text: https://secwatch.observer/filing/0001193125-26-056020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.